Increased tumor cisplatin levels in heated tumors in mice after administration of thermosensitive, large unilamellar vesicles encapsulating cisplatin.
Hyperthermia (HT)-dependent cisplatin (CDDP) release and tumor CDDP level increase after the administration of thermosensitive, large unilamellar vesicles (LUVs: LUV-1 and LUV-2) and a thermosensitive, small unilamellar vesicle (SUV: SUV-1) were examined in comparison with those following administration of a non-thermosensitive LUV (LUV-3) and a CDDP solution (Sol) in tumor bearing mice. The LUV-1 and LUV-2 released CDDP at a faster rate than SUV-1 when incubated in saline at temperatures between 41 and 44 degrees C. The blood CDDP levels after liposome administration were higher than those after Sol administration. The systemic clearance of LUV-2 was slightly larger than those of the other liposomes. The tumor CDDP levels after thermosensitive liposome administration were increased in response to HT in comparison to LUV-3 or Sol. The increased ratio for LUV-1 was the largest. The ratio of the area under the tumor CDDP level versus time curve (AUC) for LUV-1 + HT to the AUC for Sol + HT was approximately 5. The results indicate that (1) the tumor-CDDP level increase after thermosensitive liposome administration is due to CDDP release from the liposome in the blood at or adjacent to the heated tumor, (2) the increase is highly dependent on the heat sensitivity and systemic stability of the liposome, and (3) LUV, such as LUV-1, exhibit higher heat sensitivity and larger, targeted drug delivery efficiency than SUV.